The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
15 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $11,585,705 in first-year total cost, median $899,988.
Most frequent study sections
- Special Emphasis Panel[ZCA1 GRB-S (M1)]15
Most frequent institutions
- SLOAN-KETTERING INST CAN RESEARCH4
- BETH ISRAEL DEACONESS MEDICAL CENTER2
- DANA-FARBER CANCER INST1
- MASSACHUSETTS GENERAL HOSPITAL1
- MAYO CLINIC ROCHESTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | The TGF Beta Signaling Pathway in Development and Cancer1R35CA252978-01 | MASSAGUE, JOAN | SLOAN-KETTERING INST CAN RESEARCH, NY | $1,062,000 | ZCA1 |
| 2020 | Precision Prevention Research Program1R35CA253185-01 | CHAN, ANDREW T | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,007,990 | ZCA1 |
| 2020 | Mechanisms of human papillomavirus entry1R35CA242462-01A1 | DIMAIO, DANIEL C. | YALE UNIVERSITY, CT | $1,004,992 | ZCA1 |
| 2020 | The role of clonal hematopoiesis in the development and therapy of myeloid malignancies1R35CA253125-01 | EBERT, BENJAMIN LEVINE | DANA-FARBER CANCER INST, MA | $1,004,250 | ZCA1 |
| 2020 | Tissue mechanics reprograms the tissue to malignancy and metastasis1R35CA242447-01A1 | WEAVER, VALERIE MARIE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $969,000 | ZCA1 |
| 2020 | Targeting the MYC Pathway for the Treatment of Cancer1R35CA253180-01 | FELSHER, DEAN W | STANFORD UNIVERSITY, CA | $962,720 | ZCA1 |
| 2020 | Resolving the cancer relevance of predisposition gene mutations1R35CA253187-01 | COUCH, FERGUS JOSEPH | MAYO CLINIC ROCHESTER, MN | $952,518 | ZCA1 |
| 2020 | Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.1R35CA241894-01A1 | SCHEINBERG, DAVID A | SLOAN-KETTERING INST CAN RESEARCH, NY | $899,988 | ZCA1 |
| 2020 | Differential function and tumor vulnerabilities revealed by RAS membrane trafficking1R35CA253178-01 | PHILIPS, MARK REID | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $805,378 | ZCA1 |
| 2020 | Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer1R35CA253097-01 | TOKER, ALEX | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $771,175 | ZCA1 |
| 2020 | Innate immune sensors, inflammasomes, and inflammasome-mediated processes in cancer1R35CA253095-01 | KANNEGANTI, THIRUMALA-DEVI | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $721,739 | ZCA1 |
| 2020 | Homology-directed repair: BRCA2 and RAD51 paralogs1R35CA253174-01 | JASIN, MARIA | SLOAN-KETTERING INST CAN RESEARCH, NY | $704,502 | ZCA1 |
| 2020 | Therapeutic Targeting of Human AML Stem Cells1R35CA242376-01A1 | JORDAN, CRAIG T. | UNIVERSITY OF COLORADO DENVER, CO | $340,338 | ZCA1 |
| 2020 | Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies1R35CA253027-01 | WEI, WENYI | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $278,634 | ZCA1 |
| 2020 | Towards targeting the lymphoma microenvironment1R35CA252982-01 | WENDEL, HANS-GUIDO | SLOAN-KETTERING INST CAN RESEARCH, NY | $100,481 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.